The Tang Wei Lab is based in the Department of Pharmacy and Pharmaceutical Sciences at the National University of Singapore (NUS). Our research focuses on leveraging biomaterials to enhance vaccine delivery and immunoengineering strategies for improved therapeutic outcomes in cancer and other health challenges. Our goal is to develop safe, effective technologies that optimize therapy through advanced drug delivery systems. To achieve this, we integrate an interdisciplinary approach, combining biomaterials science, nanomedicine, chemistry, biomedical engineering, and molecular imaging. Current research projects include: developing novel biomaterials and nanoparticles for nucleic acid delivery (mRNA, siRNA, CRISPR-Cas9) in cancer therapy; optimizing delivery technologies for antigens and adjuvants (e.g., STING agonists) to boost vaccine efficacy; integrating biomaterials with cutting-edge approaches in targeted protein degradation (TPD) to enhance immune responses; and engineering living materials or their derivatives to modulate the immunosuppressive tumor microenvironment (TME) by altering cell-cell interactions and tumor metabolism.